Fig. 3.

LrS235 stops disease progression and reduces bone and joint damage and inflammation in rats with CIA. A. Clinical scores of paw inflammation from rats with CIA treated with vehicle (2) or with 100 μg/kg ShK-235 () every other day starting disease onset, 1 × 10⁹ cfu LrGusA () or LrS235 gavage daily (). B. Hematoxylin and eosin (Left) and safranin O/fast green (Right) staining and histology scoring (C) of joints from paws from CIA rats received different treatments. Original magnification, 10×, scale bars, 100 μm. Refer to “Histology and micro-CT” in the Materials and Methods for more details of the scoring system. D. Representative micro-CT of paws from CIA rats treated with vehicle, synthetic ShK-235 every other day, or oral gavage with LrGusA, LrS235 daily. Data presented as mean ± SEM. N = 7 to 10 rats per group. Asterisks indicate areas of cartilage erosions. *P < 0.05; **P < 0.01, ***P < 0.001, and ****P < 0.0001.